Aura Biosciences (AURA) Competitors $6.74 -0.15 (-2.18%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$6.74 0.00 (0.00%) As of 08/1/2025 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock AURA vs. ABCL, HROW, WVE, NTLA, PHVS, CVAC, CDTX, PAHC, CALT, and AUPHShould you be buying Aura Biosciences stock or one of its competitors? The main competitors of Aura Biosciences include AbCellera Biologics (ABCL), Harrow (HROW), WAVE Life Sciences (WVE), Intellia Therapeutics (NTLA), Pharvaris (PHVS), CureVac (CVAC), Cidara Therapeutics (CDTX), Phibro Animal Health (PAHC), Calliditas Therapeutics AB (publ) (CALT), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical products" industry. Aura Biosciences vs. Its Competitors AbCellera Biologics Harrow WAVE Life Sciences Intellia Therapeutics Pharvaris CureVac Cidara Therapeutics Phibro Animal Health Calliditas Therapeutics AB (publ) Aurinia Pharmaceuticals Aura Biosciences (NASDAQ:AURA) and AbCellera Biologics (NASDAQ:ABCL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment. Which has more risk and volatility, AURA or ABCL? Aura Biosciences has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500. Comparatively, AbCellera Biologics has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Does the media prefer AURA or ABCL? In the previous week, AbCellera Biologics had 5 more articles in the media than Aura Biosciences. MarketBeat recorded 5 mentions for AbCellera Biologics and 0 mentions for Aura Biosciences. AbCellera Biologics' average media sentiment score of 0.53 beat Aura Biosciences' score of 0.00 indicating that AbCellera Biologics is being referred to more favorably in the news media. Company Overall Sentiment Aura Biosciences Neutral AbCellera Biologics Positive Which has stronger earnings and valuation, AURA or ABCL? Aura Biosciences has higher earnings, but lower revenue than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAura BiosciencesN/AN/A-$86.92M-$1.90-3.55AbCellera Biologics$28.83M43.89-$162.86M-$0.56-7.57 Is AURA or ABCL more profitable? Aura Biosciences has a net margin of 0.00% compared to AbCellera Biologics' net margin of -737.56%. AbCellera Biologics' return on equity of -15.98% beat Aura Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Aura BiosciencesN/A -58.63% -49.74% AbCellera Biologics -737.56%-15.98%-12.38% Do analysts rate AURA or ABCL? Aura Biosciences currently has a consensus target price of $22.00, indicating a potential upside of 226.41%. AbCellera Biologics has a consensus target price of $8.75, indicating a potential upside of 106.37%. Given Aura Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Aura Biosciences is more favorable than AbCellera Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aura Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25AbCellera Biologics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in AURA or ABCL? 96.8% of Aura Biosciences shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 5.4% of Aura Biosciences shares are owned by company insiders. Comparatively, 28.9% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryAura Biosciences and AbCellera Biologics tied by winning 8 of the 16 factors compared between the two stocks. Get Aura Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for AURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AURA vs. The Competition Export to ExcelMetricAura BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$346.35M$3.00B$5.48B$9.51BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-3.5517.6228.6723.80Price / SalesN/A179.18373.9066.58Price / CashN/A41.9535.4557.96Price / Book2.228.508.275.55Net Income-$86.92M-$55.06M$3.24B$259.03M7 Day Performance-6.78%-3.98%-3.69%-4.59%1 Month Performance4.33%9.59%4.33%4.46%1 Year Performance-27.06%6.72%25.95%18.03% Aura Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AURAAura Biosciences1.556 of 5 stars$6.74-2.2%$22.00+226.4%-31.6%$346.35MN/A-3.5550Gap DownABCLAbCellera Biologics2.4221 of 5 stars$5.15+15.0%$8.75+69.9%+39.0%$1.34B$28.83M-9.20500News CoverageUpcoming EarningsGap UpHigh Trading VolumeHROWHarrow2.5184 of 5 stars$37.08+3.3%$63.83+72.2%+27.2%$1.32B$199.61M-66.21180Gap DownWVEWAVE Life Sciences4.6969 of 5 stars$7.87-5.6%$20.15+156.1%+40.1%$1.30B$104.94M-9.37240News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionNTLAIntellia Therapeutics4.501 of 5 stars$12.63+4.7%$33.37+164.2%-54.3%$1.25B$57.88M-2.41600News CoverageUpcoming EarningsGap DownHigh Trading VolumePHVSPharvaris1.7483 of 5 stars$23.84+2.5%$36.20+51.8%+25.5%$1.22BN/A-7.9230Positive NewsCVACCureVac4.4438 of 5 stars$5.40+0.2%$6.83+26.5%+51.1%$1.21B$579.18M5.87880News CoveragePositive NewsCDTXCidara Therapeutics3.1487 of 5 stars$57.05-4.9%$57.29+0.4%+389.1%$1.21B$1.27M-1.9490Upcoming EarningsHigh Trading VolumePAHCPhibro Animal Health4.1332 of 5 stars$29.14-0.9%$24.40-16.3%+41.1%$1.19B$1.19B37.361,940Positive NewsDividend AnnouncementCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180AUPHAurinia Pharmaceuticals2.3298 of 5 stars$8.62-0.1%$11.50+33.4%+87.0%$1.17B$235.13M30.79300Trending NewsEarnings ReportAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies AbCellera Biologics Competitors Harrow Competitors WAVE Life Sciences Competitors Intellia Therapeutics Competitors Pharvaris Competitors CureVac Competitors Cidara Therapeutics Competitors Phibro Animal Health Competitors Calliditas Therapeutics AB (publ) Competitors Aurinia Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AURA) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aura Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aura Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
